Translated title of the contribution: 13-cis-retinoic acid in the treatment of oral leukoplakia

S. Toma, P. E. Mangiante, G. Margarino, P. L. Losardo, N. Spadini, S. Valente, A. Silvestrini, M. Vincenti, R. Palumbo

Research output: Contribution to journalArticlepeer-review


Sixteen patients with oral leukoplakia were treated with oral 13-cis-retinoic acid (cRA) at progressively increasing doses. The initial dose, given for 3 months, was 0.2 mg/kg/day, increased by a further 0.2 mg/kg/day in the following 3-month cycles. The maximum dosage reached at 1.0 mg/kg/day, was given to only 2 patients (who received a total of 15 months treatment). However, 10 patients completed the cycle at 0.8 mg/kg/day (12 months treatment in total), but treatment could not continue due to toxicity (grade I and II), which was cutaneous, mucosal, and haematological (hypertriglyceridemia and hypercholesterolemia). There was grade III toxicity in the skin and mucosa in only 1 case, a patient treated at the dose of 1.0 mg/kg/day. The toxicity was reversible in all cases at the end of treatment. On the 14 evaluable patients there were 4 partial responses (PR), 3 of whom obtained at 0.2 mg/kg/day and 1 at 0.6; one complete response (CR) was reached at 0.4 mg/kg/day. The overall objective response rate was 36%, with 50% or more reduction in lesion size. After the retinoic acid treatment was stopped, patients were followed-up for 12 months; 2 patients showed regression of the responses obtained after 6 and 9 months, respectively. This study shows that oral treatment with cRA at low doses is effective and with minimal toxicity. It also suggests that a long-term duration treatment is not feasible, with doses above 0.8 mg/kg/day, mainly due to poor compliance, rather than the actual treatment-related toxicity.

Translated title of the contribution13-cis-retinoic acid in the treatment of oral leukoplakia
Original languageItalian
Pages (from-to)207-210
Number of pages4
Issue number4
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of '13-cis-retinoic acid in the treatment of oral leukoplakia'. Together they form a unique fingerprint.

Cite this